Ruth L. Martin

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Loren Lasko, Clarissa G. Jakob, Rohinton Edalji et al. · Nature · 2017 · 858 citations · Full text

Medicine, Cancer Biology, Oncology +8

Mibefradil Block of Cloned T-Type Calcium Channels

Ruth L. Martin, Jung-Ha Lee, Leanne L. Cribbs et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 241 citations

Medicine, Medicinal Chemistry, Pharmacology +15

Discovery of<i>N</i>-(4-(3-Amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N</i>‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor

Yujia Dai, Kresna Hartandi, Zhiqin Ji et al. · Journal of Medicinal Chemistry · 2007 · 185 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block

Ruth L. Martin, Jeff S. McDermott, Heinz J. Salmen et al. · Journal of Cardiovascular Pharmacology · 2004 · 179 citations

Medicine, Cardiology, Pharmacology +17

Discovery of <i>N</i>-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

Keith F. McDaniel, Le Wang, Todd Soltwedel et al. · Journal of Medicinal Chemistry · 2017 · 137 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12